Oxibendazole
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H326952

CAS#: 20559-55-1

Description: Oxibendazole, also known as SK&F-30310, SKF-30310, is a DNA polymerase inhibitor potentially for the treatment of helminth intestinal infections. Oxibendazole is laso used to protect against roundworms, strongyles, threadworms, pinworms and lungworm infestations in horses and some domestic pets. It is usually white to yellowish in appearance.

Chemical Structure

img
Oxibendazole
CAS# 20559-55-1
Instruction

Theoretical Analysis

Hodoodo Cat#: H326952
Name: Oxibendazole
CAS#: 20559-55-1
Chemical Formula: C12H15N3O3
Exact Mass: 249.11
Molecular Weight: 249.270
Elemental Analysis: C, 57.82; H, 6.07; N, 16.86; O, 19.26

Price and Availability

Size Price Availability Quantity
1g USD 250 2 Weeks
5g USD 550 2 Weeks
10g USD 850 2 Weeks
25g USD 1550 2 Weeks
Bulk inquiry

Synonym: Oxibendazole; SK&F-30310; SK&F30310; SK&F 30310; SKF-30310; SKF30310; SKF 30310. Anthelcide EQ; Loditac.

IUPAC/Chemical Name: methyl (5-propoxy-1H-benzo[d]imidazol-2-yl)carbamate

InChi Key: RAOCRURYZCVHMG-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H15N3O3/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

SMILES Code: O=C(OC)NC1=NC2=CC(OCCC)=CC=C2N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 249.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lyons ET, Tolliver SC, Kuzmina TA, Collins SS. Further evaluation in field tests of the activity of three anthelmintics (fenbendazole, oxibendazole, and pyrantel pamoate) against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010). Parasitol Res. 2011 Oct;109(4):1193-7. doi: 10.1007/s00436-011-2379-3. Epub 2011 Apr 16. PubMed PMID: 21499750.

2: Traversa D, Iorio R, Otranto D, Giangaspero A, Milillo P, Klei TR. Species-specific identification of equine cyathostomes resistant to fenbendazole and susceptible to oxibendazole and moxidectin by macroarray probing. Exp Parasitol. 2009 Jan;121(1):92-5. doi: 10.1016/j.exppara.2008.10.001. Epub 2008 Oct 8. PubMed PMID: 18950625.

3: Lyons ET, Tolliver SC, Ionita M, Collins SS. Evaluation of parasiticidal activity of fenbendazole, ivermectin, oxibendazole, and pyrantel pamoate in horse foals with emphasis on ascarids (Parascaris equorum) in field studies on five farms in Central Kentucky in 2007. Parasitol Res. 2008 Jul;103(2):287-91. doi: 10.1007/s00436-008-0966-8. Epub 2008 May 10. PubMed PMID: 18470536.

4: Magambo JK. Ultrastructural changes in Ascaris suum after oxibendazole treatment. Afr J Health Sci. 1998 Feb;5(1):38-41. PubMed PMID: 17580993.

5: Gokbulut C, Nolan AM, McKellar QA. Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses. Res Vet Sci. 2002 Feb;72(1):11-5. PubMed PMID: 12002632.

6: Overgaauw PA, Boersema JH. Anthelmintic efficacy of oxibendazole against some important nematodes in dogs and cats. Vet Q. 1998 Apr;20(2):69-72. PubMed PMID: 9563164.

7: Gottschall DW, Wang R. Depletion and bioavailability of 14C-oxibendazole residues in swine tissues. Vet Parasitol. 1996 Aug;64(1-2):83-93. PubMed PMID: 8893466.

8: Rolfe PF, Dawson KL. The efficacy of a combination anthelmintic against oxibendazole resistant small strongyles, large strongyles and ascarids in horses. Aust Vet J. 1994 Sep;71(9):304-6. PubMed PMID: 7818443.

9: Lyons ET, Drudge JH, Tolliver SC, Swerczek TW, Stamper S, Granstrom DE. Control of cambendazole-resistant small strongyles (Population S) with oxibendazole in a pony band: an 8 year field test (1984-1992). Vet Parasitol. 1994 Apr;52(3-4):271-7. PubMed PMID: 8073610.

10: Tolliver SC, Lyons ET, Drudge JH, Stamper S, Granstrom DE. Critical tests of thiabendazole, oxibendazole, and oxfendazole for drug resistance of population-B equine small strongyles (1989 and 1990). Am J Vet Res. 1993 Jun;54(6):908-13. PubMed PMID: 8323061.

11: Uhlinger C, Kristula M. Effects of alternation of drug classes on the development of oxibendazole resistance in a herd of horses. J Am Vet Med Assoc. 1992 Jul 1;201(1):51-5. PubMed PMID: 1644647.

12: Austin SM, DiPietro JA, Foreman JH, Baker GJ, Todd KS Jr. Comparison of the efficacy of ivermectin, oxibendazole, and pyrantel pamoate against 28-day Parascaris equorum larvae in the intestine of pony foals. J Am Vet Med Assoc. 1991 Jun 1;198(11):1946-9. PubMed PMID: 1874672.

13: Piché CA, Kennedy MJ, Herbers HA, Newcomb KM. Comparison of ivermectin, oxibendazole, and pyrantel pamoate in suppressing fecal egg output in horses. Can Vet J. 1991 Feb;32(2):104-7. PubMed PMID: 17423731; PubMed Central PMCID: PMC1480944.

14: McCracken RO, Lipkowitz KB. Experimental and theoretical studies of albendazole, oxibendazole, and tioxidazole. J Parasitol. 1990 Apr;76(2):180-5. PubMed PMID: 2319417.

15: Huang YX, Zhou JX, Xue ZQ, Wu YX, Chen JY, Wu HZ, Ji MH, Shen YP, Cao GQ, Wu ZX, et al. [Clinical observations on the treatment of hookworm, Ascaris and Trichuris infection with oxibendazole]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1990;8(2):100-3. Chinese. PubMed PMID: 2208619.

16: Slocombe JO, Cote JF, McMillan I. Effectiveness of oxibendazole against benzimidazole-resistant strongyles in horses. Can Vet J. 1989 Aug;30(8):663-5. PubMed PMID: 17423395; PubMed Central PMCID: PMC1681156.

17: Bauer C, Bürger HJ. Efficacy of an oxibendazole-trichlorfon paste formulation against third stage larvae of Gasterophilus intestinalis and its safety in horses. Vet Rec. 1986 Sep 20;119(12):294-6. PubMed PMID: 3535229.

18: Drudge JH, Lyons ET, Tolliver SC, Swerczek TW. Use of oxibendazole for control of cambendazole-resistant small strongyles in a band of ponies: a six-year study. Am J Vet Res. 1985 Dec;46(12):2507-11. PubMed PMID: 4083584.

19: Theodorides VJ, Nawalinski T, Chimes N, Weideman C, Free SM. Anthelmintic efficacy of oxibendazole in ponies: comparison of methods. Am J Vet Res. 1982 May;43(5):892-4. PubMed PMID: 7091856.

20: Drudge JH, Lyons ET, Tolliver SC, Kubis JE. Clinical trials of oxibendazole for control of equine internal parasites including benzimidazole-resistant small strongyles. Mod Vet Pract. 1981 Sep;62(9):679-82. PubMed PMID: 7022161.